Bioavailability of Prochlorperazine Suppositories, 25 mg

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to compare prochlorperazine plasma concentrations produced after administration of the test formulation with those produced after administration of a marketed reference product.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Padagis LLC; Paddock Laboratories, Inc.
• Treatments: Prochlorperazine

Criteria

Inclusion Criteria:

• Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening

Exclusion Criteria:

• Positive test results for HIV or Hepatitis B or C

• History of allergy or sensitivity to Prochlorperazine or related drugs